Lerdelimumab
Based on 1 Customer Validation
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 285985-06-0
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG4 lambda
Human
TGFB2
Lerdelimumab (10 μg/mL) inhibits all TGF-β2-induced effects. TGF-β2 stimulates transdifferentiation and contraction of the capsular bag and induces MMP-2 and -9 release of capsular bags[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 lambda2
ELISA, FACS, Functional assay
-
Loaded Lerdelimumab on ProA biosensor, can bind TGF beta 2/TGFB2 Protein, Human (HEK293, HY-P7119) with an affinity constant of 1.927E-09 M as determined in BLI assay.
Chemical Information
-
CAS. Nr. 285985-06-0
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Lerdelimumab]
-
Synonyms
CAT-152
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Mead AL, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3394-401. [Content Brief]
[2]. Wormstone IM, et al. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Lerdelimumab Related Classifications
HY-P99695 Related Classifications
Powered by Bioz